cn202
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 22, 2021 (NCT05028478)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming growth factor beta-1INHIBITOR
TGFB1 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05028478 | Phase 1/Phase 2 (Phase 2) | Oct 22, 2021 | Cabrini Oncology Research, Curon Biopharmaceutical (Australia) Co Pty Ltd, Novotech, Southern Medical Day Care Centre |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cabrini Oncology Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Curon Biopharmaceutical (Australia) Co Pty Ltd | For profit | 1 | 1 | 1 | 2021 |
| Novotech | For profit | 1 | 0 | 1 | 2021 |
| Southern Medical Day Care Centre | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1